Opinion

Yi-Zarn Wang v. J. Phillip Boudreaux, M.D.; Ochsner Medical Center - Kenner, L.L.C.; Ochsner Clinic Foundation; And Ochsner Health System

Court
Louisiana Court of Appeal
Filed
Jan 15, 2021
Status
Published
Author
Judge Edwin A. Lombard
On the bench
Judge Edwin A. Lombard; Judge Rosemary Ledet; Judge Tiffany G. Chase
Cited by
0 cases
Authority
More cited than 36.7%

The opinion

YI-ZARN WANG * NO. 2020-CA-0249

VERSUS *

COURT OF APPEAL

J. PHILLIP BOUDREAUX, *

M.D.; OCHSNER MEDICAL FOURTH CIRCUIT

CENTER - KENNER, L.L.C.; *

OCHSNER CLINIC STATE OF LOUISIANA

FOUNDATION; AND *******

OCHSNER HEALTH SYSTEM

APPEAL FROM

CIVIL DISTRICT COURT, ORLEANS PARISH

NO. 2017-11867, DIVISION “N-8”

Honorable Ethel Simms Julien, Judge

******

Judge Edwin A. Lombard

******

(Court composed of Judge Edwin A. Lombard, Judge Rosemary Ledet, Judge

Tiffany G. Chase)

Michael Patrick Doyle

Patrick Dennis

Jeff Avery

DOYLE LLP

3401 Allen Pkwy, Suite 100

Houston, TX 77019

Paul M. Sterbcow

Ian F. Taylor

LEWIS, KULLMAN, STERBCOW & ABRAMSON, LLC

601 Poydras St., Suite 2615

New Orleans, LA 70130

COUNSEL FOR PLAINTIFF/APPELLANT

Jeff Landry

Attorney General

Kelli M. Khalaf

J. Marc Vezina

Special Assistants

Attorney General

VEZINA AND GATTUSO, L.L.C.

401 Weyer St., P. O. Box 461

Gretna, LA 70054

Pauline F. Hardin

Tyler J. Rench

JONES WALKER LLP

201 St. Charles Avenue, 49th Floor

New Orleans, LA 70170

Judith W. Giorlando

BREAZEALE, SACHSE & WILSON, L.L.P.

301 Main St., Suite 2300

One American Place

Baton Rouge, LA 70801

COUNSEL FOR DEFENDANTS/APPELLEES

AFFIRMED

JANUARY 15, 2020

EAL

RML

TGC

By devolutive appeal, Yi-Zarn Wang, M.D. (the plaintiff), challenges the

district court judgments in favor of the defendants, Ochsner Medical Center-

Kenner, L.L.C., Ochsner Clinic Foundation, Ochsner Health System (hereinafter

“Ochsner”), and Dr. J. Philip Boudreaux, dismissing all of Dr. Yang’s claims with

prejudice. After de novo review of the record in light of the applicable law and

arguments of the parties, we affirm the district court judgments.

Relevant Facts and Procedural History

In 2005, Dr. Wang was hired by Louisiana State University Health Sciences

Center New Orleans (“LSU”) as a faculty member; concomitantly, Dr. Wang

applied for and received clinical privileges at Ochsner as non-employed (by

Ochsner) medical staff. As required by Ochsner, Dr. Wang re-applied every two

years to maintain his privileges at Ochsner. By letter of June 30, 2015, Dr. Wang’s

most recent appointment to the active Ochsner Medical Staff (for the term

7/31/2015-7/31/2017) was confirmed; the confirmation letter included a copy of

the current Ochsner Code of Conduct (“Policy 13”) and Dr. Wang was advised that

1

the current Ochsner Bylaws (pertaining to clinical privileges as implemented by

the Ochsner Medical Executive Committee (“MEC”)) were available for his

review in the Medical Staff office. It is undisputed that these documents constitute

the contract between the parties.

In November 2015, an Ochsner patient1 diagnosed with appendicitis

expressed concern about Dr. Wang’s non-surgical medical management of his

appendicitis and requested a second opinion. Subsequently, Dr. Wang received a

letter (dated December 18, 2015) from the Ochsner Medical Leadership Council

(“MLC”) informing him that: (1) the patient’s complaint about Dr. Wang’s course

of treatment had been reviewed; (2) non-surgical medical management was neither

recognized nor authorized treatment by Ochsner for patients clinically diagnoed

with appendicitis; and (3) the matter had been referred to the MEC for further

review.

In February 2016, Dr. Wang received a letter from the MEC confirming its

review and advising Dr. Wang in clear terms “non-surgical medical management

of patients with appendicitis is not a privilege/practice available to Ochsner

Medical Staff.” (Emphasis added). In April 2016, Dr. Wang treated another

Ochsner patient diagnosed with appendicitis in the Emergency Room (“ER”) and

transferred to general surgery. Dr. Wang confirmed the diagnosis but, contrary to

the explicit instructions received from the MEC and MLC, made the following

entry into the patient’s record on April 20, 2016:

.1 The medical records in this matter are sealed.

2

. . . I have [sic] a long discussion with the patient about the treatment

option evolution in the last 20 years. I have [sic] told her about my

view and the literatures [sic] that back up my evidences based practice

and the position of the hospital committee I also advised her she can

request for [sic] another surgeon to provide care if she prefers. She

said she likes my view and [sic] willing to address her problem with

abx as the first line tx.

The patient, discharged from Ochsner on April 22, 2016, underwent an

emergency appendectomy surgery that same day at Touro Infirmary.

On May 27, 2016, Dr. Wang received a hand-delivered letter from the MEC

informing him that his non-surgical treatment of the April 2016 Ochsner

appendicitis patient was in direct violation of its instructions to Dr. Wang to

discontinue all non-surgical medical management of patients with appendicitis. In

addition, the MEC found Dr. Wang’s medical entry regarding his disagreement

with the Ochsner policy regarding appendicitis care to be derogatory, impugning

the Ochsner quality of care and inappropriately disclosing confidential peer review

information in violation of the Ochsner Code of Conduct. Accordingly, Dr. Wang

was informed that: (1) his clinical privileges were suspended for a five day period,

May 27-June 1, 2016; and (2) to maintain his clinical privileges Dr. Wang was

required to return a signed copy of the letter to signify his agreement to the

personal professional conduct plan put forth in the letter requiring him to comply

with MEC policy directives and refrain from making derogatory comments about

the Ochsner quality of care or disclosing information pertaining to the Ochsner

confidential peer review process; and (3) his failure to provide this signed copy of

the letter to the Medical Staff office by the allotted time would constitute “a

voluntary resignation of your OMC-K Medical Staff membership and clinical

privileges.” (Emphasis in original).

3

Dr. Wang signed the receipt verifying he received the letter dated May 27,

2016, on that same date. Nonetheless, he failed to timely return the requisite

signed copy of the letter acknowledging his acceptance and agreement to the

proposed professional conduct plan. As forewarned, Dr. Wang’s clinical privileges

were relinquished as of May 31, 2016.

Rather than re-apply for clinical privileges (the appropriate course of action

as advised by both Ochsner and Dr. Wang’s supervisor on the LSU faculty2), Dr.

Wang filed a federal lawsuit against Ochsner and his Ochsner/LSU colleague, Dr.

J. Philip Boudreaux, alleging that they conspired against him in violation of the

federal Racketeer Influenced and Corrupt Organizations Act of 1970 (“RICO”).

The federal district court dismissed Dr. Wang’s RICO claims with prejudice.3

Wang v. Ochsner Med. Ctr-Kenner, LLC, 17-5134 (E.D. La. 12/7/2017), 2017 WL

10065713.

Shortly thereafter, Dr. Wang filed this lawsuit in state court, again naming

Ochsner and Dr. Boudreaux4 as defendants and alleging that Ochsner and Dr.

Boudreaux, their agents, employees, and “other third parties”5 acted in concert in a

civil conspiracy to defraud him and other illegal and wrongful activities by

diverting his patients to Dr. Boudreaux. More specifically, Dr. Wang asserted

claims for (1) breach of contract; (2) negligent misrepresentation; (3) tortious

2

Notably, when a practitioner voluntarily relinquishes privileges, as in this case, the practitioner

can immediately submit a new application of reinstatement of membership or clinical privilege. If

the practitioner’s re-application is denied, then the right to a hearing attaches, pursuant to Article

8.1 of the Bylaws. Accordingly, to maintain his privileges at Ochsner or, alternatively, receive a

hearing on the matter, Dr. Wang should have filed a reapplication for clinical privileges as advised

by both Ochsner and LSU supervisors.

3

Dr. Wang’s state claims were dismissed without prejudice.

4

Although the acts took place in in Jefferson Parish, Dr. Wang filed the claim in Orleans Parish

because Dr. Boudreaux is a resident of Orleans Parish,

5

Dr. Wang specifically names the MEC, another Ochsner doctor and an Ochsner employee as

co-conspirators.

4

interference with Dr. Wang’s relationships in the medical community; and (4)

violation of the Louisiana Unfair Trade Practices and Consumer Protection Law

(LUPTA) La. Rev. Stat. 51:4101, et seq. Pursuant to La. Code Civ. Proc. art.

3601, Dr. Wang also sought injunctive and declaratory relief with respect to his

suspension from practice and loss of hospital privileges.

On April 15, 2019, Dr. Wang filed a motion for partial summary judgment

on his breach of contract claim; on May 22, 2019, Ochsner filed a cross-motion for

partial summary judgment on Dr. Wang’s breach of contract claim, pointing out

that its action fully complied with the contract between the parties. After a

hearing on June 21, 2019, the district court entered judgment on July 18, 2019,

granting Ochsner’s cross-motion for partial summary judgment, denying Dr.

Wang’s motion for partial summary judgment, and dismissing Dr. Wang’s breach

of contract claim with prejudice.

Subsequently, both Ochsner and Dr. Boudreaux filed motions for summary

judgment on Dr. Wang’s remaining claims: Ochsner pointed out that as part of his

2015 reapplication for clinical privileges Dr. Wang granted broad immunity to

Ochsner and agreed not to sue for any actions taken by Ochsner towards him; Dr.

Boudreaux pointed out that Dr. Wang cannot satisfy his burden of proof at trial on

his claims made against Dr. Boudreaux. The district court agreed and, on February

3, 2020, granted summary judgment in favor of Ochsner and Dr. Boudreaux and

dismissed Dr. Wang’s lawsuit with prejudice.

Dr. Wang timely filed this appeal challenging the district court judgments.

Standard of Review

A district court's ruling on summary judgment is reviewed de novo, using

the same criteria that governs the district court's consideration of whether summary

5

judgment is appropriate, i.e., whether there is any genuine issue of material fact

and whether the movant is entitled to summary judgment as a matter of law.

Wright v. Louisiana Power & Light, 2006-1181, p. 17 (La. 3/9/07), 951 So.2d

1058, 1070.

Summary Judgment

A motion for summary judgment is a procedural device used when there is

no genuine issue of material fact for all or part of the relief prayed for by a litigant.

Beer Indus. League of Louisiana v. City of New Orleans, 2018-0280, p. 7 (La.

6/27/18), 251 So. 3d 380, 385-86. Summary judgment, designed to secure the just,

speedy, and inexpensive determination of civil actions (with the exception of

certain domestic matters), is favored under Louisiana law. La. Code Civ. Proc. art.

966(A)(2). Accordingly, “[a]fter an opportunity for adequate discovery, a motion

for summary judgment shall be granted if the motion, memorandum, and

supporting documents show that there is no genuine issue of material fact and that

the mover is entitled to judgment as a matter of law.” La. Code Civ. Proc. art.

966(A)(3).

Burden of Proof

On motion for summary judgment, the burden of proof remains with the

movant. La. Code Crim. Proc. art. 966(D)(1). However, when a moving party will

not bear the burden of proof at trial and points out there is an absence of factual

support for one or more elements essential to the adverse party’s claim, action, or

defense, then the burden is on the non-moving party to produce factual support

sufficient to establish that he will be able to satisfy his evidentiary burden of proof

at trial. Id.

6

Dr. Wang’s Claims against Ochsner

Dr. Wang argues that the district court erred in denying his Motion for

Partial Summary Judgment on his breach of contract claim, granting Ochsner’s

Cross-Motion for Summary Judgment on Dr. Wang’s breach of contract claim, and

granting Ochsner’s Motion for Summary Judgment on the remaining claims

against Ochsner.

Applicable law

The essential elements of a breach of contract claim are: (1) the existence of

a contract; (2) the party’s breach thereof; and (3) resulting damages. Padian v.

Algiers Charter School Association, Inc., 2019-0201, p. 3 (La. App. 4 Cir.

6/19/19), 274 So.3d 1266, 1268 (citation omitted). When the words of a contract

are clear and explicit and lead to no absurd consequences, no further interpretation

may be made in search of the parties' intent. La. Civ. Code art. 2046.

Discussion

In his motion for partial summary judgment, Dr. Wang asserts that (1) a

contract existed based on his application to Ochsner for privileges and the parties’

mutual agreement to Ochsner’s Bylaws, and (2) Ochsner breached this contract

when it revoked Dr. Wang’s privileges without following the hearing procedures

as required in the Bylaws.

In its response and cross-motion, Ochsner points out that its course of action

fully complied with Ochsner policies and procedures and, hence, the contract

between the parties. In support of its motion, Ochsner submits copies of the

documents creating the contract, specifically, Dr. Wang’s most recent (2015) re-

application (entitled Conditions of Reappointment Application-Release and

7

Immunity), the Ochsner Bylaws of the Medical Staff,6 including Medical Staff

Policies and, most particularly, Policy 13 - the Ochsner Code of Conduct. By

signing his 2015 re-application, Dr. Wang confirmed that he read the Bylaws and

related documents and was bound by them. Thus, by the terms of the contract

between the parties, Dr. Wang acknowledged and agreed to the following in return

for clinical privileges at Ochsner:

1) He would abide by the Bylaws and Policies, and other requirements

of the Medical Staff and the Hospital. Bylaws art. 3.4(D).

2) He would participate in peer review, performance improvement,

risk management, case management, and other review and

improvement activities as requested. Bylaws art. 3.4(G).

3) He was subject to review by the Medical Staff and his performance

could be evaluated whenever the MEC deemed it necessary. Bylaws

art. 3.4(J).

4) He was subject to Ochsner’s peer review process, a procedure

specifically designed to address issues related to an individual’s

clinical practice and/or professional conduct and to resolve in a

collegial manner all questions raised through the voluntary and

responsive action of the individual involved. Bylaws art. 7.1.

5) Intervention efforts by the MLC were part of Ochsner’s

professional and peer review activities. Bylaws art. 7.1 (A).

6) Most specifically, Ochsner intervention efforts were designed to

review and follow up on questions raised about the clinical practice

and/or conduct of its staff members through peer counseling,

education and related steps such as advising colleagues of all

applicable policies regarding appropriate behavior through peer

review, monitoring, and letters of guidance to share and provide

relevant information, including any variations from clinical protocols

or guidelines, in order to assist individuals to conform their practice to

appropriate norms. Bylaws art. 7.1(B).

7) Determination of applicable intervention efforts were within the

6

Bylaws of the Medical Staff, Section 3.4 entitled “General Obligations and Conditions for

Medical Staff Appointment/Reappointment” clearly states that “By submitting an application of

reapplication for Staff membership, the applicant signifies agreement to fulfill the following

obligations and conditions”: . . . (D) Abide by these Bylaws and the Policies, and other

requirements of the Medical Staff and the Hospital.”

8

discretion of the MLC.

8) The determination as to whether a matter was handled in

accordance with a Policy, such as the Policy on Physician Health or

the Code of Conduct and whether to conduct further review and

determination under the Bylaws was within the discretion of the

MLC. Bylaws art. 7.1 (E).

9) When a serious matter was raised or collegial efforts did not

resolve an issue involving the clinical practice (including the care,

treatment, or management of a patient or patients) of a member of the

Medical Staff, the matter would referred to the MEC to make a

sufficient inquiry as to the credibility of the question. Bylaws art. 7.2.

10) The MEC determined the course of action to follow in matters

involving questions concerning clinical competence and professional

conduct. Bylaws art. 7.3(A).

11) Derogatory comments and inappropriate medical entries

impugning the quality of care being provided at Ochsner, as well as

the refusal to abide by Medical Staff requirements delineated in the

Bylaws and Policies and an unwillingness to work cooperatively and

harmoniously are specific examples of inappropriate conduct subject

to review under Policy 13, the Code of Conduct. Policy 13.2(E), (F),

& (H).

12) Once the MLC determined that an incident of inappropriate

conduct has occurred, its options included (but were not limited to)

sending the practitioner a letter of guidance about the incident and/or

a letter of warning or reprimand, particularly if there have been prior

incidents and a pattern may be developing. Policy 13.5(B)(2) & (4).

13) It was within the discretion of the MLC to continue to utilize the

steps outlined in Policy 13 if there was a reasonable likelihood that

such action would resolve the concerns but at any point the MLC

could refer the matter to the MEC. Policy 13.5(E) & 13.6(A).

14) It was within the discretion of the MEC to issue a letter of

warning or reprimand; require a behavior modification course; impose

a “personal” code of conduct on the practitioner making continued

appointment and clinical privileges contingent on the practitioner’s

adherence to the prescribed code of conduct; and to suspend the

practitioner’s clinical privileges for less than 30 days. The imposition

of any of these actions does not entitle the practitioner to a hearing or

an appeal. Policy 13.6(B)(3), (4), (5), & (6).

15) Finally, the Conditions of Reappointment Application signed by

Dr. Wang in submitting his 2015 re-application clearly states that by

re-applying for clinical privileges, he extended absolute immunity to

9

Ochsner, agreed not to sue, and released from any and all liability

Ochsner, its medical staff, and appropriate third parties for actions

taken towards him. Conditions of Reappointment Application Section

B(1).

In his reply brief and response to Ochsner’s cross-motion, Dr. Wang

acknowledges his contract with Ochsner consists of the documents related to his

re-application, namely the Bylaws and Policy 13. Inexplicably, however, he

continues to insist that Ochsner lacked a factual basis for its actions and that a

hearing was required. As the above summary of the pertinent contract provisions

indicates, Dr. Wang’s clinical privileges at Ochsner were just that, privileges

granted subject to his adherence to Ochsner rules and policies, not a protected

entitlement subject to constitutional due process rights.

Dr. Wang does not dispute that he advocated non-surgical treatment of

appendicitis for an Ochsner patient, that the patient complained and sought a

second opinion, that he was advised by the MEC and MLC that non-surgical

treatment of appendicitis was not acceptable at Ochsner, that he continued to

pursue non-surgical treatment with a subsequent Ochsner patient despite specific

instructions that this was contrary to Ochsner policy, that he received the letter

advising him of imposition of a 5-day suspension with a personal professional

conduct plan and a deadline to return a signed copy of the letter as

acknowledgment of his agreement to the conduct plan for maintenance of his

clinical privileges, and that he failed to timely comply with this mandate. Viewing

these undisputed facts in light of the contract between the parties, Ochsner is

entitled to summary judgment on Dr. Wang’s breach of contract claim as a matter

of law. Accordingly, the district court did not err in denying Dr. Wang’s motion

and granting summary judgment in favor of Ochsner on the breach of contract

10

claim.

The remaining claims in Dr. Wang’s petition against Ochsner are as follows:

Ochsner negligently misrepresented that it was authorized to terminate his

privileges; Ochsner tortuously interfered with Dr. Wang’s business relations by

terminating his clinical privileges; Ochsner violated LUTPA by misrepresenting to

his patients how he lost his privileges (Ochsner purportedly told Dr. Wang’s

patients that he retired rather than that his privileges were terminated for failing to

adhere to Ochsner rules and policies; Dr. Wang claims this is actionable because

he did not retire); and Ochsner should be compelled to remove the suspension and

revocation of Dr. Wang’s privileges from its files. All of these claims flow from

Dr. Wang’s breach of contract claim and are within the broad immunity granted by

Dr. Wang to Ochsner. In his motion for partial summary judgment on the breach

of contract claim, Dr. Wang argued that Ochsner’s contractual-waiver defense was

invalid because Ochsner maliciously breached its contract with him. In its cross-

motion for partial summary judgment on the breach of contract claim, Ochsner

addressed the substantive issue – its compliance with the contract between the

parties – and the district court granted summary judgment in favor of Ochsner on

that issue, denying Dr. Wang’s motion on the breach of contract claim, as well as

his motion on Ochsner’s affirmative contractual-defense. Because there was no

breach of contract by Ochsner, much less a vicious one, the broad contractual

immunity granted by Dr. Wang to Ochsner is valid.

Accordingly, after de novo review of the motions for summary judgment

between Ochsner and Dr. Wang, we find no genuine issue of material fact exists

between the parties and Ochsner is entitled to summary judgment and dismissal of

Dr. Wang’s claims as a matter of law.

11

Dr. Wang’s Claims against Dr. Boudreaux

In his petition for damages, Dr. Wang also named his colleague, Dr.

Boudreaux, as a defendant, alleging that Dr. Boudreaux acted fraudulently in

concert with others to divert his patients by misrepresenting his availability and in

violation of LUPTA. Specifically, Dr. Wang alleges that Dr. Boudreaux, with the

aid of a Ochsner staff member, was responsible for steering patients from Dr.

Wang to himself and this resulted in a decrease in the number of patients Dr. Wang

treated and, concomitantly, in his income.

Applicable Law

“Fraud is a misrepresentation or a suppression of the truth made with the

intention to either obtain an unjust advantage for one party or to cause a loss or

inconvenience to the other.” La. Civ. Code art. 1953. “The two essential elements

of fraud are the intent to defraud or gain and unfair advantage and actual or

probable damage.” Dutton & Vaughan, Inc. Spurney, (La. App. 4th Cir. 1992),

600 2d 1992, 698. Fraud cannot be predicated on negligence, no matter how gross;

fraudulent intent, which constitutes the intent to deceive, is a necessary element of

fraud. Whitehead v. American Coachworks, Inc. 2002-0027, p. 6 (La. App. 1 Cir.

12/20/02), 837 So.2d 678, 682.

LUTPA makes “unfair methods of competition and unfair or deceptive acts

or practices in the conduct of any trade or commerce” unlawful. La. Rev. Stat.

51:1405. “A practice is unfair when it offends established public policy and when

the practice is unethical, oppressive, unscrupulous or substantially injurious.”

NOLA 180 v. Treasure Chest Casino, LLC, 2011-853, p. 5 (La. App. 5 Cir.

3/27/12), 91 So.3d 446, 457 (citations and internal quotations omitted).

Traditionally, causes of action under LUPTA are limited to consumers and

12

business competitors. Id., “[C]ourts have repeatedly held that, under this statute,

the plaintiff must show the alleged conduct offends established public policy and . .

. is immoral, unethical, oppressive, unscrupulous, or substantially injurious.”

Cheramie Services, Inc. v. Shell Deepwater Production, Inc., 2009-1633, p. 10 (La.

4/23/10), 35 So.3d 1053, 1059 (citation and internal quotations omitted).

Discussion

It is undisputed that Dr. Wang and Dr. Boudreaux were both neuroendocrine

cancer specialists on the LSU faculty with clinical privileges at Ochsner. Prior to

2013, Dr. Wang’s compensation was based on seniority and the number of

surgeries (“RVUs”) he performed but, in 2013, he entered into a revenue sharing

agreement with Dr. Boudreaux wherein they shared all surgical fees, as well as

clinical call and evaluation fees.

In his motion for summary judgment, Dr. Boudreaux points out that Dr.

Wang will be unable to produce evidence at trial to support his allegations of fraud

or of any effort to steer his patients towards Dr. Boudreaux. In support of his

motion for summary judgment, Dr. Boudreaux submits, in pertinent part, the

following deposition testimony:

1) Dr. Wang conceded that Dr. Boudreaux did not want Dr. Wang to

leave because “[w]e only have two surgeons on the service” and, if

one left, the other would be on call every day and night; in addition,

Dr. Wang conceded this operational strategy prevented internal

competition and there was no benefit to Dr. Boudreaux to have more

patients than Dr. Wang.

2) Dr. Wang conceded he only scheduled one half day per week to see

patients at the clinic; Dr. Boudreaux had four clinic days per week for

seeing patients. Dr. Wang did not schedule surgeries before 9:30 am;

Dr. Boudreaux began his surgery schedule at 7:30 am.

2) Dr. Wang stated that in the 2014-2016 period, his RVUs dropped

(Dr. Wang performed 87, 86, and 25 surgical procedures; Dr.

Boudreaux performed 255, 22, and 206 in the same period but,

13

because of the agreement with Dr. Boudreaux, their incomes remained

comparable (Dr. Wang’s compensation from July 1, 2015 to June 30,

2016, was $362,010; Dr. Boudreaux’s was $362,677).

(3) Dr. Wang stated that his 2016 employment contract with LSU

required clinical privileges at Ochsner, Touro Infirmary, or University

Medical Center and that he retired from LSU in December 2016; he

did not have clinical privileges at any of these hospitals between

losing his privileges at Ochsner and retiring from LSU. Dr. Wang

testified that he began working for Baylor on January 8, 2018, and

received over $400,000 in compensation for that year.

4) Dr. Wang conceded that it was the policy of the Neuroendocrine

Clinic that patients were first seen by the Director of the clinic or

another doctor and then assigned to a surgeon; Dr. Boudreaux was not

involved in the process.

5) Dr. Wang’s witness, Ann Porter (a nurse at the Neuroendocrine

Clinic) testified by deposition that the new patient protocol required

initial screening and then assignment to a surgeon on a rotational

basis; no changes were made to the surgical schedule once it was

made.

6) Although Dr. Wang alleged that his patients were steered to Dr.

Boudreaux by providing misleading information about his retirement

from LSU, he was unable to provide specific information, stating that

he thought one of his patients was told in the “late part of – of 2016, I

believe” that he had retired from LSU; Dr. Wang retired in December

2016.

In response, Dr. Wang argues that he has provided sufficient evidence of

loss to support his LUPTA claim. However, Dr. Wang’s only evidence submitted

in support of this is to point to Dr. Boudreaux’s deposition testimony wherein Dr.

Boudreaux concedes that his income increased after Dr. Wang left Ochsner. Dr.

Wang also alleges that Dr. Boudreaux had an inappropriate relationship with an

Ochsner nurse who, based on this relationship, misled Dr. Wang’s patients as to his

availability after Dr. Wang left Ochsner. As evidence of this, Dr. Wang points to

emails from the staff member who, in response to a query from the Ochsner CEO,

states that after Dr. Wang left Ochsner her staff had been instructed to inform

patients that Dr. Wang was not available and, if patients “pushed” the issue, they

14

were advised to tell them that “we do not know” of his availability and, ultimately,

to offer them the opportunity to see other physicians. Dr. Wang points out in his

brief, however, that the staff member “further confirmed that this misleading

message to patients [the claims that Dr. Wang was not available] came from the

administration.”

Thus, the only evidence Dr. Wang offers to support his contentions of Dr.

Boudreaux’s purported fraud and LUPTA violation are that Dr. Boudreaux’s

income increased once he became the only endocrine surgical specialist at the

clinic after Dr. Wang lost his Ochsner clinical privileges (thereby invalidating the

revenue sharing agreement that Dr. Boudreaux had entered into so that he was not

constantly on call); and that the Ochsner administration instructed its staff to

characterize Dr. Wang’s absence as being unavailable rather than, presumably,

explaining the circumstances of Dr. Wang’s loss of clinical privileges. Notably,

when asked for specifics as to his allegations that Ochsner misrepresented his

availability, Dr. Wang could only reference a wife of a patient who he thought had

been told he retired in December 2016.

Dr. Wang did, in fact, retire from LSU in December 2016. Dr. Wang does

not present any evidence that he was “available” to his patients after he left

Ochsner or that he provided the particulars of his availability to Ochsner for

disbursement. Moreover, in light of his lack of clinical privileges in the interim

between leaving Ochsner and retiring from LSU (his application for privileges at

UMC and Touro were withdrawn when he retired from LSU, indicating that

neither application had been accepted), it is difficult to imagine a scenario in which

Dr. Wang was “available” in any practical sense to patients. Finally, Dr. Wang has

failed to show any economic damages to support his LUPTA claims; while he had

15

clinical privileges at Ochsner, his income was comparable to that of Dr.

Boudreaux; his loss of income due to the lack of clinical privileges (presumably

required for any kind of surgery) is due to his own actions and not attributable to

Dr. Boudreaux; and by his own admission, his income increased with his new

position at Baylor which, presumably, was accompanied with the necessary

clinical privileges.

Accordingly, after de novo review of Dr. Boudreaux’s motion for summary

judgment, we find that, as Dr. Boudreaux points out, Dr. Wang cannot meet his

burden of proof at trial. As previously discussed, Dr. Wang’s loss of clinical

privileges at Ochsner was based on his own decisions and not attributable to Dr.

Boudreaux. As Dr. Wang conceded, there was no benefit in Dr. Boudreaux

gaining more patients than Dr. Wang as the income remained evenly divided

whether or not the surgeries were equitably distributed. Similarly, Dr. Wang

submits evidence clearly indicating that the Ochsner staff responses to Dr. Wang’s

patients regarding Dr. Wang’s availability are not attributable to Dr. Boudreaux.

Accordingly, Dr. Boudreaux is entitled to summary judgment as a matter of law.

Conclusion

The judgments of the district court are affirmed.

AFFIRMED

16

This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.

A word about cookies

We need a few to keep you signed in and the library working. The rest help us see which pages people use and where they get stuck. They stay off unless you say yes.